Isophosphamide
Phase 2Small molecule
Isophosphamide is one of 85 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
109 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Rituxan
RochePhase 3
Oncovin
Eli LillyPhase 3
Polivy
RochePhase 3
Gemzar
Johnson & JohnsonPhase 3
Adriamycin
PfizerPhase 3
Gazyva
RochePhase 3
Oncovin
Eli LillyPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteosarcoma1 trial
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT05590572·148 enrolled
Diffuse Large B-Cell Lymphoma1 trial
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05784987·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Isophosphamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details